"Airway Management Isolation Chamber" in Patent Application Approval Process (USPTO 20230147927).

Předmět:
Zdroj: Medical Letter on the CDC & FDA; 6/2/2023, p1750-1750, 1p
Abstrakt: Business, COVID-19, Coronaviridae, Coronavirus, Enterovirus, Genetics, Hepatitis, Hepatitis Viruses, Hepatovirus, Hepatitis E Virus, Hepevirus, Influenza A Virus, Influenza B Virus, Liver Diseases and Conditions, Nidovirales, Parechovirus, RNA Viruses, Respiratory Syncytial Viruses, Rhinovirus, Risk and Prevention, Rubella Virus, SARS Virus, SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2, United States Army, Vertebrate Viruses, Viral, Viral RNA, Virology, Viruses, Yellow Fever Virus COVID-19 is typically caused by the spread of the virus in respiratory droplets and/or particles from an infected patient and the virus has been shown to persist in the environment for significant periods with up to 3 hours of viability in aerosols and up to 3 days on surfaces. [Extracted from the article]
Databáze: Complementary Index